| Title: |
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT |
| Authors: |
Baron F.; Labopin M.; Tischer J.; Raiola A. M.; Vydra J.; Blaise D.; Chiusolo P.; Stolzel F.; Fanin R.; Chevallier P.; Nagler A.; Ciceri F.; Mohty M. |
| Contributors: |
Baron, F.; Labopin, M.; Tischer, J.; Raiola, A. M.; Vydra, J.; Blaise, D.; Chiusolo, P.; Stolzel, F.; Fanin, R.; Chevallier, P.; Nagler, A.; Ciceri, F.; Mohty, M. |
| Publisher Information: |
BioMed Central Ltd |
| Publication Year: |
2023 |
| Subject Terms: |
Acute myeloid leukemia; AML; HLA-haploidentical; Mismatched unrelated donor; Post-transplant cyclophosphamide; PTCy |
| Description: |
The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated. Here, we addressed this issue in patients with active AML at transplantation. 2-year cumulative incidences of relapse and leukemia-free survival (LFS) were 49% and 32.3%, respectively. There were no associations between acute nor chronic GVHD of any grade and lower relapse incidence. However, grade I acute GVHD was associated with better LFS (HR = 0.71, 95% CI 0.51–0.99, P = 0.04). In contrast, grade III–IV acute (HR = 3.09, 95% CI 1.87–5.12, P < 0.0001) as well as extensive chronic (HR = 3.3, 95% CI 1.81–6.04, P = 0.0001) GVHD correlated with higher nonrelapse mortality leading to lower LFS (HR = 1.36, 95% CI 0.99–1.86, P = 0.056 and HR = 1.97, 95% CI 1.35–2.89, P = 0.0004, respectively). In conclusion, these data suggest a dissociation of graft-versus-leukemia effects from GVHD in patients with active AML treated with PTCy-based Haplo-HCT. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/36782226; info:eu-repo/semantics/altIdentifier/wos/WOS:000936581000001; volume:16; issue:1; numberofpages:5; journal:JOURNAL OF HEMATOLOGY & ONCOLOGY; https://hdl.handle.net/20.500.11768/138302 |
| DOI: |
10.1186/s13045-023-01403-x |
| Availability: |
https://hdl.handle.net/20.500.11768/138302; https://doi.org/10.1186/s13045-023-01403-x; https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01403-x |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.55F6917B |
| Database: |
BASE |